Imaging tryptophan metabolism in children with epilepsy

癫痫儿童色氨酸代谢成像

基本信息

  • 批准号:
    7173741
  • 负责人:
  • 金额:
    $ 28.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-01-01 至 2008-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Approximately 0.5% to 1.0% of the population suffers from epilepsy. Fifteen to 20% of these individuals have seizures which cannot be controlled with anticonvulsants. Epilepsy is particularly devastating in children, in whom recurrent prolonged seizures may result in impaired cognitive development. The major goal of this proposal is to provide improved preoperative localization of epileptogenic brain tissue in children with medically uncontrolled neocortical epilepsy who are being treated with surgical resection of the epileptic focus. The central hypothesis of this proposal is that abnormalities in brain tryptophan metabolism via the serotonin and/or kynurenine pathways contribute to the pathophysiology and localization of neocortical epilepsy. Brain tryptophan metabolism will be measured in vivo in drug-resistant epilepsy patients using the tracer alpha [C-11 ]methyl-L-tryptophan (AMT) with positron emission tomography (PET). Our preliminary data show increased AMT accumulation in epileptogenic cortex in approximately one-half of patients assessed for epilepsy surgery. The focus of increased AMT uptake is typically much smaller than the large areas of hypometabolism seen on glucose metabolism PET scanning. In the present grant application, we propose to confirm and extend these findings by comparing AMT PET results to quantitative electrophysiological measures obtained during presurgical evaluation. In order to better understand the pathophysiology underlying altered AMT uptake by epileptic brain tissue, we will perform biochemical measurements in the tissue which is surgically resected for control of intractable epilepsy. Three specific aims will be addressed: 1. To determine the extent to which AMT PET and glucose metabolism PET regions of abnormality localize neocortical epileptogenic regions defined by subdural electrode recordings in both lesional and nonlesional neocortical epilepsy. 2. To determine whether resection of cortex with increased AMT uptake is related to outcome of epilepsy surgery. 3. To determine the underlying biochemical mechanism for the observed focal increases in cortical AMT uptake in patients with epilepsy. Our research will contribute to a better understanding of the pathophysiology and improve localization of focal epilepsy.
描述(由申请人提供):大约0.5%至1.0%的人口患有癫痫。这些人中有15%至20%的癫痫发作不能用抗惊厥药控制。癫痫在儿童中尤其具有破坏性,反复长时间癫痫发作可能导致认知发育受损。本建议的主要目标是提供改进的术前定位癫痫脑组织的儿童与医学不受控制的新皮质癫痫谁正在接受手术切除的癫痫病灶。该提议的中心假设是,通过5-羟色胺和/或犬尿氨酸途径的脑色氨酸代谢异常有助于新皮质癫痫的病理生理学和定位。将使用示踪剂α [C-11 ]甲基-L-色氨酸(AMT)和正电子发射断层扫描(PET)在体内测量耐药性癫痫患者的脑色氨酸代谢。我们的初步数据显示,在接受癫痫手术的患者中,约有一半的患者在致癫痫皮质中的AMT积累增加。AMT摄取增加的焦点通常比葡萄糖代谢PET扫描上看到的大面积代谢减退小得多。在目前的拨款申请中,我们建议通过比较AMT PET结果与术前评估期间获得的定量电生理测量结果来确认和扩展这些发现。为了更好地了解癫痫脑组织AMT摄取改变的病理生理学基础,我们将在手术切除以控制顽固性癫痫的组织中进行生化测量。将讨论三个具体目标:1。确定AMT PET和葡萄糖代谢PET异常区域定位于损伤性和非损伤性新皮质癫痫中硬膜下电极记录定义的新皮质致痫区域的程度。2.确定AMT摄取增加的皮质切除术是否与癫痫手术结局相关。3.确定癫痫患者皮质AMT摄取局灶性增加的潜在生化机制。我们的研究将有助于更好地了解病理生理学和改善定位局灶性癫痫。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DIANE C CHUGANI其他文献

DIANE C CHUGANI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DIANE C CHUGANI', 18)}}的其他基金

Children with autism spectrum disorders in developing countries
发展中国家患有自闭症谱系障碍的儿童
  • 批准号:
    8648285
  • 财政年份:
    2013
  • 资助金额:
    $ 28.97万
  • 项目类别:
Early Pharmacotherapy Guided by Biomarkers in Autism
自闭症生物标志物指导的早期药物治疗
  • 批准号:
    8528190
  • 财政年份:
    2012
  • 资助金额:
    $ 28.97万
  • 项目类别:
Early Pharmacotherapy Guided by Biomarkers in Autism
自闭症生物标志物指导的早期药物治疗
  • 批准号:
    8528189
  • 财政年份:
    2008
  • 资助金额:
    $ 28.97万
  • 项目类别:
Early Pharmacotherapy Guided by Biomarkers in Autism
自闭症生物标志物指导的早期药物治疗
  • 批准号:
    8053740
  • 财政年份:
    2008
  • 资助金额:
    $ 28.97万
  • 项目类别:
Early Pharmacotherapy Guided by Biomarkers in Autism
自闭症生物标志物指导的早期药物治疗
  • 批准号:
    7560375
  • 财政年份:
    2008
  • 资助金额:
    $ 28.97万
  • 项目类别:
Early Pharmacotherapy Guided by Biomarkers in Autism
自闭症生物标志物指导的早期药物治疗
  • 批准号:
    7277369
  • 财政年份:
    2008
  • 资助金额:
    $ 28.97万
  • 项目类别:
Early Pharmacotherapy Guided by Biomarkers in Autism
自闭症生物标志物指导的早期药物治疗
  • 批准号:
    8231524
  • 财政年份:
    2008
  • 资助金额:
    $ 28.97万
  • 项目类别:
Early Pharmacotherapy Guided by Biomarkers in Autism
自闭症生物标志物指导的早期药物治疗
  • 批准号:
    7696269
  • 财政年份:
    2008
  • 资助金额:
    $ 28.97万
  • 项目类别:
Early Pharmacotherapy Guided by Biomarkers in Autism
自闭症生物标志物指导的早期药物治疗
  • 批准号:
    7817184
  • 财政年份:
    2008
  • 资助金额:
    $ 28.97万
  • 项目类别:
Imaging tryptophan metabolism in children with epilepsy
癫痫儿童色氨酸代谢成像
  • 批准号:
    7001243
  • 财政年份:
    2004
  • 资助金额:
    $ 28.97万
  • 项目类别:

相似海外基金

Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
  • 批准号:
    10004277
  • 财政年份:
    2020
  • 资助金额:
    $ 28.97万
  • 项目类别:
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
  • 批准号:
    10475298
  • 财政年份:
    2020
  • 资助金额:
    $ 28.97万
  • 项目类别:
Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents
用于神经毒剂的新型水溶性辅助抗惊厥药
  • 批准号:
    10013749
  • 财政年份:
    2020
  • 资助金额:
    $ 28.97万
  • 项目类别:
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
  • 批准号:
    10693904
  • 财政年份:
    2020
  • 资助金额:
    $ 28.97万
  • 项目类别:
Study on how anticonvulsants affect car driving
抗惊厥药如何影响汽车驾驶的研究
  • 批准号:
    20K17977
  • 财政年份:
    2020
  • 资助金额:
    $ 28.97万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents
用于神经毒剂的新型水溶性辅助抗惊厥药
  • 批准号:
    10266034
  • 财政年份:
    2020
  • 资助金额:
    $ 28.97万
  • 项目类别:
Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents
用于神经毒剂的新型水溶性辅助抗惊厥药
  • 批准号:
    10475109
  • 财政年份:
    2020
  • 资助金额:
    $ 28.97万
  • 项目类别:
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
  • 批准号:
    10248384
  • 财政年份:
    2020
  • 资助金额:
    $ 28.97万
  • 项目类别:
Prevention of neuropathic pain by antidepressants and anticonvulsants: in vivo patch-clamp analysis
抗抑郁药和抗惊厥药预防神经性疼痛:体内膜片钳分析
  • 批准号:
    24592355
  • 财政年份:
    2012
  • 资助金额:
    $ 28.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Anticonvulsants, ischemic seizures and regeneration in the immature brain
抗惊厥药、缺血性癫痫发作和未成熟大脑的再生
  • 批准号:
    8492175
  • 财政年份:
    2009
  • 资助金额:
    $ 28.97万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了